Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$1.16M, compared with $2.02M a year earlier. Trailing-twelve-month net change in cash was -$3.83M. Over 3 fiscal years it compounded at -80.5% a year.
Context
- Net change in cash amounted to 0.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Net change in cash grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$1.16M or moves back toward the trailing-twelve-month quarterly average of -$957K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (642K) USD
- Year-over-year change
- +60.7%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (642K) | +60.7% |
| FY2024 | 2024-12-31 | (1.63M) | +74.9% |
| FY2023 | 2023-12-31 | (6.49M) | +92.5% |
| FY2022 | 2022-12-31 | (86.36M) | -198.4% |
| FY2021 | 2021-12-31 | 87.75M | — |
Net Change in Cash vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 net change in cash of $3.83M is the smallest of the 8 companies compared; the peer median is $10.43M.
- Its year-over-year change of -194.8% is the 6th highest of 8, against a peer median of -37.7%.
- Net change in cash amounts to 1.8% of revenue for TMCI, versus a peer median of 8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $111.74M | +182.9% | — | 129.5% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $108.11M | -189.4% | — | 113.7% |
| LTM Mar 2026 | $21.18M | -278.5% | — | 8.7% | |
| LTM Mar 2026 | $18.1M | -37.7% | -28.9% | 6.0% | |
| LTM Mar 2026 | $13.04M | +650.1% | — | 2.3% | |
| LTM Mar 2026 | $10.43M | +124.5% | — | 8.2% | |
| LTM Mar 2026 | $9.46M | -356.8% | -45.8% | 1.7% | |
| LTM Mar 2026 | $3.83M | -194.8% | -80.5% | 1.8% | |
| Peer median (excluding TMCI) | $10.43M | -37.7% | -37.4% | 8.2% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| Deferred Income Tax | 419K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.41M | 8.11M | 17.35M | 30.6M | 33.82M |
| Change in Working Capital | (1.33M) | (5.81M) | (9.74M) | (25.43M) | (8.58M) |
| Accounts Receivables | (4.23M) | (11.04M) | (9.3M) | (5.69M) | (2.09M) |
| Inventory | (3.09M) | (8.77M) | (9.85M) | (10.01M) | 3.22M |
| Accounts Payables | 1.79M | 4.61M | 3.17M | (1.31M) | (3.8M) |
| Other Working Capital | 4.19M | 9.39M | 6.24M | (8.42M) | (5.92M) |
| Other Non-Cash Items | 176K | 7.73M | 1.99M | 4.99M | 7.29M |
| Operating Cash Flow | (17.19M) | (30.65M) | (34.58M) | (37.17M) | (15.97M) |
| Capital Expenditures | (2.71M) | (14.84M) | (11.46M) | (11.59M) | (13.52M) |
| Acquisitions (Net) | 0 | 61.68M | (20M) | 0 | 0 |
| Purchases of Investments | 0 | (63.41M) | (169.87M) | (71.58M) | (40.57M) |
| Sales of Investments | 0 | 1.73M | 120.02M | 118.55M | 67.34M |
| Other Investing Activities | 0 | (61.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (76.52M) | (81.3M) | 35.38M | 13.25M |
| Debt Repayment | (1.79M) | 19.61M | 0 | 0 | 2.43M |
| Common Stock Issued | 109.44M | 2.19M | 109.4M | 428K | 546K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (989K) | (13K) | (268K) | (902K) |
| Financing Cash Flow | 107.65M | 20.81M | 109.38M | 160K | 2.08M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 87.75M | (86.36M) | (6.49M) | (1.63M) | (642K) |
| Free Cash Flow | (19.9M) | (45.49M) | (46.03M) | (48.76M) | (29.49M) |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.